Acute Myeloid Leukemia | Topics

Whole-Genome Sequencing May Improve Prognosis Accuracy for AML/MDS Versus Traditional Cytogenetics
April 01, 2021

According to a single-institution study of patients with a known or suspected diagnosis of AML or MDS, whole-genome sequencing may provide better predictive ability of patients’ risk status than traditional methods.

Confirmatory Trial of Gilteritinib Meets Primary End Point of Improving OS in Relapsed/Refractory FLT3+ AML
March 31, 2021

Treatment with gilteritinib, compared with salvage chemotherapy, improved overall survival in patients with relapsed/refractory FLT3 mutation–positive acute myeloid leukemia, according to a planned interim analysis of a phase 3 trial.

FDA Approves Expanded Indication of Daunorubicin/Cytarabine to Include Children With AML
March 31, 2021

The FDA approved a revised label for daunorubicin/cytarabine to treat newly-diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged 1 and older.